Figure 2From: Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program Overall survival according to the best response to trabectedin. Overall survival of patients whose best response was: partial response (light brown), stable disease (purple), progressive disease (green), or non evaluable (blue). Log-rank p value, p < 0,0001.Back to article page